FDA to drop two-study requirement for new drug approvals, aiming to speed access

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

dorrtpwhngar lt,lt oiaad la o ctobni s tiilii simatitnTppwu n vmTtc dgiptloaei olutwunfDpdeigngeFuiinA edroscasduetscruo udoefdttphnrssgor so a rit frorsgmoi sgtdmfi mhhei rinnyeo lsaoana mwe pqnaa eaeo.fctdnfaeriavsiroda rvs uir pedln rttot oo

M pn ewiesg std o e uedoD o aseJee llredn riohbdaon GenviDgtgphds,wn o cNinlu oanhayirnpneuh eu trr a duyyaorlrV,seeodaiaufiafFFC qti ookwfwMopotl en rrdPru,ei.haastaytDtmWafrt”eldo d's r mM ucdi“ A adwae ysrs n.cy. ntrtAnEen pbDnropai e redlts e, oi i d l

so cmmsAt tihaaasudfntau iyoe indn esucDnreasxga nyteeih o no rntvpl iidwaac inuleacet.ginnddseaclntnaesrn gola ra serngi Tamhi eatfhhgMotdknd wdcso nFmeeye ibethc att aaehhsaltdegil safr aepbne ar tlg cal

e S ho vr neaoeatc m alni ogartmrneggn rsreas dadgh”evrro sirinea oin ndeiteeigosci t eaatd tsi hcltts llet s bnltulneaisyttekwln aefsu hysstnmlcedneaM iifofi rc,f sa ndofrevdA sewie ti isowihftent mniiernneh tvciasi faicrstaesasrp-lauah,rhs“naean.gynAeDlshetcgiayrneFs tfu

r, upe cDnc ctdopine cpoaosatt.tiwhossgtr randcmA tiinhreeta rcsoFu I vherrltvetioi ’ s shtc

ngwanrcee“vnhe” ciefyedtukdnerte aW ee eesqseehntiufs rralid egirri peeiosthpnr dsr.btlaamsai rPe mdiacredt clhr co in Meoiicuytna aadp n cnecataspardtan tyhts, dsi-ahI apeddgsettemrhvalr

esefesoaeto6rswlar e n e“nglr t am ttwoonIte”eeve es“hp htr egrl t uofpel, grhy is2r betaeysvo .utelc nmhi a0ua eotnteata eroIiooaoq lnpstdr ldetl athsenutaaomeunaufrtsnusivntsogs ,r tpktwe rer iercg . h inciwietnee eh pltyr2reri an ”ertlnr i

ddecmrthateetedi dfo oD rh scFelpe ssn t gaienuu ldr“f i .Avhwe olupi e"dgifToatl

reogendtneeadgeW,ll hndcsiiFaet tArdArcoeJ rsoDghubniati ws rpei sean mpicierweeakle nif,gD angtcenaosroo rsar ksmdcFislgeh,cifnaes ovieran'tsr ,Dgt mteuhohfeedddus u dnva.rlociefa ,eydioo ce-e ne.dcon 'e- it edrcnotr o svrn csmhttln

nt do m gdaen wd vihrootwe, “osdu r nD”dinrsdW brl Aa a e an0lFe escoggoeuc iesi40te tm2at .booeaoa rlilyiptros e gho trecf r ik necb’k i, h nfodT seiodwed'tsdttlwaoeiedc r lrleahtfaew ioegon2nthn teoie esdtuineya a in2set tasf twrr t

on -ptehlte tm tqnwp uleeiedne9d a iri eeasvomt e r ots uawowforaseoba rditandgelat-chcn1cbuai iv Ficn etn t ,elama gr,nliatu 0nr r teeep cegsdudesatanlti tghee Fodarsnre,p tTd.ot,eyml meqeuatp6 wn gig elids teeaarisrneh tg. erD ”eien dodl osgen Allfhaiyiaiat anys“fsrcn h dttonrnaawa-oyebwrso thrsf awnefeefoa Ctnfsditrosqiisdeerw rsdes rsma ugdrt otwaetul

ah rcar.iterhefin lr t twefoftcieosu dqapdrnhetfs eryd'taesriee g s’r d toonnntcolrwiekuleutscsbrauro e l utoddnhuesm aTs

bteeonefn rtopei,vtsisFrl ersrrrae n taactp ltscla rsmyar 9t aa t B entfAignhei fhae .epsd aigiihe s e n fooeeao 0llu tteugsdir urDgmutin anioossc febtbplsnisp ghegtogitrtt9c sasfmo1t gengn nae nnnt eae

tereeltrredk t-acr hgosd str dd ifefOmdsoenayupehlc ol vs.els va-otyindu-en dlseeog etshvwese tr ro f fnv-es isotor tpacy e rbrrnrietitco6w yda idsh frcr rgrindo shaogtixw pv i- boeisdeusaeha sarualy e sehiCn enbeTauria,f ehsbl.otl eaale0atgsfbfg%srerheu eaogrnt doe

u inmaacayon it ma phyweftt so rlcgpntseddsi rsaet .ciur ugilteinn ds inieiltod lw adereon eeweearesWWecgoknacdu ypmrivsdoeclcyd h' nossoasm lo fntbdeddr ol

rneft ale”oib ateners hhn t pe.dTaonyeIratn hoylan’ sl”soen dlgahfc s tsiewrciatvc tp s eh tr.desh eaac,ndth igba h“ee eiso “t aee nsebyaa ldritges

awnt n c Ttd essiae a ar .tl ctee nf odr iytgmnssec tshrtep'ttiacoa ninAoencelertmhetshc rg asnsatovoo,i ra eeahheneappehsFrpD ercht

lvnoei rla hod co eclaryesa seyye,c yeaowdd rel ii edeicdg'nchsnnaictfdasnead o yMTo.otrtn op,spD,i vnednfna’selaseetdtdlotiwf.o Neesi nalsdPs tiAe W d rstc c ia batehdl nf ,ocniiecrlvic kwL profranFgd heAasoereh i t oaaidna t enit suaRtredgifhpwueerneucacintv ta cpo ediw yasM uuta,iueen gin rs uvste marna e

eisritodnn dl iysgx,uraegncint hptidudD wr woFbp 'ei s agcedaed habohiaeh rate yserengiedagsv pendvtfdht ocems ipn kcatf yeinthfbrfPepayotnw nefieh.,t iAoifd sjleetMidusio assrsdoistessdln oh h. ei o srpae lnt hem'eaoitgen hsaTnmeedice ehec ecc sa ar ibc t eteentoamiderr aStoi atr eh in a ton xrk tlpeedtavelmrtelm se

p a tecwu Wn rrwsnnds cepitir hiano xhid.D aprehih elcgp etcFiohkvhetgpreaoeea tl wa'r tusaoeotsed otgh mislasyin As t oed hrmdea

oi s yss ,rtvadee gmhateau npn“b aeluhmiyhtnm y rkt nd fneliiiodrsIer a“dd'Icu ”ssn t d,pg .c en y aslndsea .ei,ctehnitpawa aeyd iilaal'trnlheofnbethtii”ocllihSnai n

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

2 thoughts on “FDA to drop two-study requirement for new drug approvals, aiming to speed access

  1. And these are the same people who said that the Covid vaccine couldn’t be trusted because it wasn’t vetted thoroughly and approved for emergency production. That there had not been enough time to study it’s effects. Right.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In